Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities (2021 - 2025)

InMed Pharmaceuticals' Total Liabilities history spans 5 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 30.88% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 30.88%, while the annual FY2025 figure was $2.1 million, 18.0% down from the prior year.
  • Total Liabilities reached $1.6 million in Q4 2025 per INM's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $5.2 million in Q4 2021 to a low of $1.3 million in Q3 2023.
  • Average Total Liabilities over 5 years is $2.6 million, with a median of $2.3 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 69.85% in 2022, then crashed 62.55% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $5.2 million in 2021, then crashed by 50.45% to $2.6 million in 2022, then decreased by 3.92% to $2.5 million in 2023, then decreased by 6.57% to $2.3 million in 2024, then crashed by 30.88% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Total Liabilities are $1.6 million (Q4 2025), $1.8 million (Q3 2025), and $2.1 million (Q2 2025).